176 related articles for article (PubMed ID: 89118)
21. Effects of human anaphylatoxins on guinea pig atria.
Huey R; Bloor CM; Hugli TE
Immunopharmacology; 1984 Dec; 8(3-4):147-54. PubMed ID: 6335143
[TBL] [Abstract][Full Text] [Related]
22. Activation of the third complement component (C3) and C3a generation in cardiac anaphylaxis: histamine release and associated inotropic and chronotropic effects.
del Balzo U; Polley MJ; Levi R
J Pharmacol Exp Ther; 1988 Sep; 246(3):911-6. PubMed ID: 2458450
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effects of C4a on chemoattractant and secretagogue functions of the other anaphylatoxins via Gi protein-adenylyl cyclase inhibition pathway in mast cells.
Xie P; Nishiura H; Semba U; Chen J; Zhao R; Kuniyasu A; Yamamoto T
Int Immunopharmacol; 2012 Jan; 12(1):158-68. PubMed ID: 22155625
[TBL] [Abstract][Full Text] [Related]
24. Release of leukotrienes from guinea pig lung stimulated by C5ades Arg anaphylatoxin.
Stimler NP; Bach MK; Bloor CM; Hugli TE
J Immunol; 1982 May; 128(5):2247-52. PubMed ID: 6174625
[TBL] [Abstract][Full Text] [Related]
25. Platelet-serotonin release by C3a and C5a: two independent pathways of activation.
Meuer S; Ecker U; Hadding U; Bitter-Suermann D
J Immunol; 1981 Apr; 126(4):1506-9. PubMed ID: 7204973
[TBL] [Abstract][Full Text] [Related]
26. Anaphylatoxin binding and degradation by rat peritoneal mast cells. Mechanisms of degranulation and control.
Fukuoka Y; Hugli TE
J Immunol; 1990 Sep; 145(6):1851-8. PubMed ID: 1697312
[TBL] [Abstract][Full Text] [Related]
27. The active site of C3a anaphylatoxin.
Caporale LH; Tippett PS; Erickson BW; Hugli TE
J Biol Chem; 1980 Nov; 255(22):10758-63. PubMed ID: 6968751
[TBL] [Abstract][Full Text] [Related]
28. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a.
Reed SL; Ember JA; Herdman DS; DiScipio RG; Hugli TE; Gigli I
J Immunol; 1995 Jul; 155(1):266-74. PubMed ID: 7602103
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells.
Takabayashi T; Shimizu S; Clark BD; Beinborn M; Burke JF; Gelfand JA
Surgery; 2004 May; 135(5):544-54. PubMed ID: 15118592
[TBL] [Abstract][Full Text] [Related]
30. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin.
Hugli TE; Erickson BW
Proc Natl Acad Sci U S A; 1977 May; 74(5):1826-30. PubMed ID: 266705
[TBL] [Abstract][Full Text] [Related]
31. Anaphylatoxin-induced release of histamine from in vitro perfused guinea pig kidney.
Abdullah NA; Assem ES; Damerau B
Agents Actions; 1988 Apr; 23(3-4):181-4. PubMed ID: 2455983
[TBL] [Abstract][Full Text] [Related]
32. Prevention of anaphylatoxin formation by high-dose corticosteroids in total hip arthroplasty.
Gammer W; Bengtson A; Heideman M
Prog Clin Biol Res; 1989; 308():879-83. PubMed ID: 2789402
[No Abstract] [Full Text] [Related]
33. The C terminus of the anaphylatoxin C3a generated upon complement activation represents a neoantigenic determinant with diagnostic potential.
Burger R; Zilow G; Bader A; Friedlein A; Naser W
J Immunol; 1988 Jul; 141(2):553-8. PubMed ID: 2454995
[TBL] [Abstract][Full Text] [Related]
34. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
Langone JJ; Das C; Bennett D; Terman DS
J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
[TBL] [Abstract][Full Text] [Related]
35. Cellular receptors to the anaphylatoxins C3a and C5a.
Huey R; Fukuoka Y; Hoeprich PD; Hugli TE
Biochem Soc Symp; 1986; 51():69-81. PubMed ID: 3545212
[TBL] [Abstract][Full Text] [Related]
36. Anaphylatoxin-mediated regulation of human and murine immune responses.
Morgan EL; Weigle WO; Hugli TE
Fed Proc; 1984 Jul; 43(10):2543-7. PubMed ID: 6610569
[TBL] [Abstract][Full Text] [Related]
37. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins.
Basta M; Van Goor F; Luccioli S; Billings EM; Vortmeyer AO; Baranyi L; Szebeni J; Alving CR; Carroll MC; Berkower I; Stojilkovic SS; Metcalfe DD
Nat Med; 2003 Apr; 9(4):431-8. PubMed ID: 12612546
[TBL] [Abstract][Full Text] [Related]
38. The effects of the anaphylatoxins C3a and C5a on isolated mast cells from rat and man.
Jürgensen H; Behrendt H; Damerau B; Schmutzler W
Agents Actions; 1986 Apr; 18(1-2):153-4. PubMed ID: 2425572
[TBL] [Abstract][Full Text] [Related]
39. Cardiac dysfunction caused by purified human C3a anaphylatoxin.
del Balzo UH; Levi R; Polley MJ
Proc Natl Acad Sci U S A; 1985 Feb; 82(3):886-90. PubMed ID: 2579381
[TBL] [Abstract][Full Text] [Related]
40. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
